Precision medicine and molecular target drugs in pediatric hematologic malignancies: acute lymphoblastic leukemia

DOI Web Site PubMed Open Access
  • TAKITA Junko
    Kyoto University, Graduate School of Medicine, Department of Pediatrics

Bibliographic Information

Other Title
  • 小児造血器腫瘍における精密医療と治療標的
  • 小児造血器腫瘍における精密医療と治療標的 : 急性リンパ性白血病
  • ショウニ ゾウケツキ シュヨウ ニ オケル セイミツ イリョウ ト チリョウ ヒョウテキ : キュウセイ リンパセイ ハッケツビョウ
  • —急性リンパ性白血病—

Search this article

Abstract

<p>Recent advances in genomic analysis technology have revolutionized precision medicine, especially with respect to the diagnosis, prognosis, and treatment of pediatric cancers. Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric cancer; genetic abnormalities associated with ALL are useful for the diagnosis and risk stratification in patients with ALL. Thus, genomic medicine (clinical sequencing) in pediatric ALL at diagnosis would help in the improvement of prognostic prediction and risk stratification. Recently, integrated genetic analysis using next generation sequencing technology revealed the full genetic landscape of pediatric ALL. These studies disclosed that in addition to fusion genes, aberrations of cell proliferation pathways and epigenetic regulations are also involved in the pathogenesis of pediatric ALL. Therefore, the realization of genomic medicine is an urgent necessity for improving the outcomes of pediatric patients diagnosed with ALL.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 61 (6), 657-664, 2020

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top